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Available online 23 February 2013AbstractBackground: Internationally, there is no consensus on the pathology protocol to be used to examine the sentinel lymph node (SN) in breast
cancer patients. Previously, we reported that ultra-staging led to more axillary lymph node dissections (ALND). The question was, whether
ultra-staging is effective in reducing the risk of regional relapse.
Methods: From January 2002 to July 2003, 541 patients from 4 hospitals were prospectively registered when they underwent a SN biopsy.
In hospitals A, B, and C, 3 levels of the SN were examined pathologically, whereas in hospital D at least 7 additional levels were examined.
Patients with a positive SN, including isolated tumor cells, underwent an ALND. This analysis focuses on the 341 patients with a negative
SN. Primary endpoint was 5-year regional recurrence rate.
Results: In hospital D 34% of the patients had a negative SN as compared to 71% in hospitals A, B, and C combined ( p < 0.001). At 5 years
follow-up, 9 (2.6%) patients had developed a regional lymph node relapse. In hospital D none of the patients had a regional recurrence, as
compared to 9 (2.9%) cases of recurrence in hospitals A, B, and C.
Conclusion: The less intensified SN pathology protocol appeared to be associated with a slightly increased risk of regional recurrence. The
absolute risk was still less than 3%, and does not seem to justify the intensified SN pathology protocol of hospital D.
 2013 Elsevier Ltd.
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The axillary lymph node status is one of the most
important prognostic factors in breast cancer.1 Nowadays,
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Open access under the Elsevier OA license.introduction of population-based breast cancer screening.
With the risk of shoulder dysfunction and lymph edema
of the arm, an ALND for axillary staging should be pre-
vented whenever possible.2
Therefore, the sentinel lymph node (SN) procedure was
introduced during the late 1990s.3 Based on figures from
the pre-SN era, it was assumed that a completion ALND
could be avoided in approximately 60% of patients with
operable breast cancer by carrying out a SN biopsy.4
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a positive non-SN varies from only 2%e9%. For instance,
in the NSABP B-32 study the SN biopsy false-negative rate
was 9.8%.5 This seems to be an acceptable rate, if missed,
especially when one considers that an increasing number of
these patients are treated with adjuvant systemic therapy,
reducing the risk that these undetected non-SN metastases
will ever become clinically apparent.
Recently, the results from the ACOSOG Z0011 were
reported, randomizing patients with 1 or 2 H&E-positive
SN to observation or ALND.3 Five-year regional recurrence
rate was 0.9% for SN only compared to 0.5% for ALND
( p ¼ 0.11). Adjuvant systemic therapy was used in the
majority of patients (97%). In the IBCSG Trial 23-01,
931 patients were randomized between ALND and no
ALND when patients had minimal SN involvement.6 Min-
imal involvement was defined as metastases of 2.0 mm in
size, including presence of isolated tumor cells. After 5
years follow-up less than 1% of patients had an axillary re-
currence with no significant difference between both treated
arms. Again of note, 92% of patients received breast con-
serving surgery with adjuvant radiotherapy, and 96% of pa-
tients received systemic therapy.
Internationally, it is recommended to examine the SN
with hematoxylin-eosin (H&E) at, at least, 3 levels of the
paraffin block, with immunohistochemistry (IHC) to be
used in case of doubt. In the Netherlands, these minimal
recommendations actually led to different local protocols.
In some hospitals more than the minimally required number
of levels is routinely investigated. In the eastern part of the
Netherlands, 3 large teaching hospitals and 1 university
hospital registered all their SN procedures prospectively
during 18 months in the years 2002 and 2003. Based on
this registry, we reported earlier that a very intensive
pathology protocol in 1 hospital, led to a high detection fre-
quency of isolated tumor cells in the SN. At the time, a com-
pletion ALND was recommended for all these patients. As
a consequence more than twice as many patients underwent
a completion ALND in the hospital with the intensified pa-
thology protocol as compared with the hospitals who used
the standard intensive pathology protocol (66% versus
29%; p < 0.0001).7
In this present study we report the follow-up data of pa-
tients in these 4 hospitals who had a negative SN, and there-
fore did not undergo an additional ALND.
The obvious question was, whether ultra-staging, and
thus more patients needing to undergo an additional
ALND, is an effective way of reducing the risk of relapse.
Methods
During eighteen months in the years 2002 and 2003
(January 2002eJune 2003), consecutive patients from 4
hospitals (A, B, C, and D) were prospectively registered
when they underwent a SN biopsy because of a cT1/
T2N0Mx breast tumor. Patients were excluded from a SNbiopsy when there was presence of multifocality of the
primary breast tumor, radiation therapy of the breast or ax-
illa in the past, when patients had received neo-adjuvant
systemic therapy, or when the SN was not detectable. The
ethical committee approved the investigational protocol.
The prospectively collected data included the lymph
node status with number of nodes examined, number of
positive nodes, size of metastases, classification according
to the tumor node metastasis (TNM) categories defined in
the 6th edition of the TNM Classification of Malignant Tu-
mors,8 and the detection method (H&E/IHC). These items
were separately registered for SNs and non-SNs. Also pri-
mary tumor characteristics (localization, tumor size, histol-
ogy, histological grade, lymph and/or blood vessel invasion,
hormone receptor status), patient characteristics (age), in-
formation on the surgical procedure (SN biopsy with or
without ALND, lumpectomy or mastectomy, and various
combinations), and information on adjuvant therapy (sys-
temic and/or radiotherapy) were collected.
The surgical procedure was, in all 4 hospitals, in accor-
dance to the Dutch guideline for treatment of breast cancer.9
That is, SN localization was performed using the combined
technique of blue dye and radioisotope in all patients. In
the presence of isolated tumor cells, micro-, or macro-
metastases in the SN, a completionALNDwas recommended.
The Dutch guideline for treatment of breast cancer de-
scribes only theminimal criteria concerning the SN pathology
protocol. It is advised to examine the SN with H&E at, at
least, 3 levels of the paraffin block with IHC to be used in
case of doubt. As a result, in hospitals A, B, and C, 3 levels
of the SN were pathologically examined, whereas in hospital
D, at least 7 additional levels were examined (at least 10 levels
in total). In the absence of apparent metastases with H&E ex-
amination, IHC examination was performed in all 4 hospitals.
According to the international TNM-classification
2002, isolated tumor cells, micro-metastases, and macro-
metastases were classified as follows: isolated tumor cells
[pN0(iþ)] are defined as solitary tumor cells or tumor cell
clusters with a size of 0.2 mm or less. Micro-metastases
[pN1mi] are more than 0.2 mm and maximally 2.0 mm in
size. Macro-metastases are >2.0 mm in size. For the SN
findings, ‘sn’ was added between brackets [pN(sn)].
This present analysis focuses on the SN negative patients
in hospitals A, B, C, and D. These SN negative patients did
not undergo a completion ALND.
For all patients still alive, follow-up data were collected
up to July 1st 2008, guaranteeing a follow-up period of at
least 5 years.
Follow-up of patients was done in line with the national
guidelines.9 In short: in the first year 3-monthly visit with
physical examinations, in the second year 6-monthly, and
thereafter yearly. All patients with remaining breast tissue
underwent a yearly mammography and if indicated also
an MRI scan. An ultrasound of the axilla was not routinely
recommended. Axillary and infra- and supraclavicular
lymph node recurrence was considered regional recurrence.
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currence, involving axillary and infra- and supraclavicular
sites. The period to regional recurrence was defined as
the interval from the date of diagnosis to regional recur-
rence. All regional recurrences were recorded, irrespective
of presence of distant metastases. Patients who died before
the end of follow-up were censored. Follow-up was cen-
sored at July 1st 2008.
To determine whether an association exists between the
SN pathology protocol and regional recurrence rate, we
compared the outcome for hospital D versus hospital A,
B, and C.
The baseline characteristics of the 4 hospitals were com-
pared with chi-square tests.
The hazard rate for regional recurrence for 5 years
follow-up was determined using life-table analysis, re-
ported with 95% confidence interval (CI). Differences
between hospitals D versus A, B, and C were analyzed
by using the logrank-test.
A p-value <0.05 was considered statistically significant.
ResultsPatient characteristicsWe registered 198 eligible patients in hospital A, of
which 134 (67.6%) patients had a negative SN. In hospital
B 120 out of 153 (78.4%) patients had a negative SN, 59Table 1
Patient and primary tumor characteristics of SN negative patients per hospital.
Baseline characteristics Hospital A Hospital B
Number of patients
N ¼ 131 (%)
Number of pati
N ¼ 113 (%)
Age
<50 30 (22.9) 26 (23.0)
50e<60 47 (35.9) 28 (24.8)
60e<70 29 (22.1) 31 (27.4)
70 25 (19.1) 28 (24.8)
Tumor size (cm)a
1.0 22 (16.8) 42 (37.8)
1.1e2.0 61 (46.6) 51 (46.0)
2.1e3.0 38 (29.0) 13 (11.7)
>3.0 10 (7.6) 5 (4.5)
Histological gradeb
I 30 (23.1) 49 (44.1)
II 61 (46.9) 47 (42.3)
III 39 (30.0) 15 (13.6)
Hormone-receptor statusc
ER and/or PgR þ 120 (91.6) 88 (77.9)
ER and PgR  11 (8.4) 25 (22.1)
Lymph and/or blood vessel invasion
No 124 (94.7) 109 (96.5)
Yes 7 (5.3) 4 (3.5)
a In 3 patients pathological tumor size was missing.
b In 5 patients histological grade was missing.
c In 2 patients hormone receptor status was missing; ER: estrogen receptor; Pout of 104 (56.7%) patients in hospital C, and 28 out of
86 (32.6%) patients in hospital D.
Patients in hospitalDwere more often diagnosed with iso-
lated tumor cells (34.9% versus 5.3% in A, B, and C,
p < 0.001), which resulted in more completion ALNDs.
Sixty-nine percent of patients in hospitals A, B, and C, as
compared to 33% of patients in hospital D did not undergo
a completion ALND, because of a negative SN ( p< 0.0001).
In total, 341 patients (63% of all registered patients) were
SN negative, and did not undergo an additional ALND. Pa-
tient and primary tumor characteristics for the SN negative
patients are shown in Table 1. There were overall no differ-
ences between hospital D versus hospitals A, B, and C.Risk of regional lymph node recurrenceAtafollow-upofatleast5years,9patientsshowedaregional
lymph node relapse. Of these patients 5 patients underwent
amastectomy, and 4 patients underwent breast conserving sur-
geryfollowedbyradiotherapy.Only4outof9patientswhohad
a recurrence receivedadjuvant systemic therapy(Table3).Five
(1.5%) patients had an axillary lymph node recurrence and 4
(1.2%) patients a supraclavicular recurrence (Table 2). There
were no patients with combined relapse.
Based on actuarial cumulative risk analysis for regional
recurrence, the 5-year regional recurrence rate was 2.4%
(95% CI 0.8e4.0).
At this moment, none of the patients with a regional re-
lapse had a distant relapse, and all patients with axillary
lymph node recurrence underwent a delayed ALND.Hospital C Hospital D p-value
ents Number of patients
N ¼ 59 (%)
Number of patients
N ¼ 28 (%)
Hospital D versus
A, B, and C
0.799
15 (25.4) 6 (21.4)
17 (28.8) 10 (35.7)
16 (27.1) 5 (17.9)
11 (18.7) 7 (25.0)
0.158
16 (27.6) 12 (42.9)
30 (51.7) 9 (32.1)
8 (13.8) 4 (14.3)
4 (6.9) 3 (10.7)
0.979
20 (33.9) 9 (34.6)
25 (42.4) 11 (42.3)
14 (23.7) 6 (23.1)
0.339
47 (79.7) 20 (76.9)
12 (20.3) 6 (23.1)
0.129
57 (96.6) 25 (89.3)
2 (3.4) 3 (10.7)
gR: progesterone receptor.
Table 2
Recurrence pattern for SN negative patients per hospital and the total group.
Hospital A Hospital B Hospital C Hospital D Total
Number of
patients N (%)
Number of
patients N (%)
Number of
patients N (%)
Number of
patients N (%)
Number of
patients N (%)
Total number SN procedures/patients 198 153 104 86 541
SN negative patients 134 (67.6) 120 (78.4) 59 (56.7) 28 (32.6) 341 (63.0)
Axillary recurrence 3 (2.2) 0 2 (3.4) 0 5 (1.5)
Supraclavicular recurrence 1 (0.7) 3 (2.5) 0 0 4 (1.2)
Local recurrence 0 4 (3.3) 1 (1.7) 0 5 (1.5)
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rence rate for hospital A was 3.0% (95% CI 0.0e6.0), for
hospital B 1.7% (95% CI 0.0e4.1), and 3.4% (95% CI
0.0e8.2) for hospital C. There were no regional recurrences
in hospital D (Fig. 1). When taken hospitals A, B, and C
together, the 5-year regional recurrence rate was 2.6%
(95% CI 0.8e4.4), as compared to 0.0% in hospital D
( p ¼ 0.37).
Table 3 shows patient and primary tumor characteristics,
as well as the timeframe to nodal recurrence, of the 9 cases
with regional lymph node recurrence.
All patients were 50 years of age or older and had an ER
or PgR positive tumor. Five of 9 patients had not received
adjuvant systemic therapy.
At a follow-up of 60e78 months, median time to recur-
rence was 27 months with a range of 4e66 months.
Discussion
We reported before that further intensification of the SN
pathology protocol, beyond the minimal recommendations,
resulted in 37% more ALNDs because of higher detection
frequency of SN isolated tumor cells.7 Whether such a policy
would reduce the number of recurrences, was the subject of
this present study. In hospital D, using ultra-staging of the
SN, no lymph node recurrences occurred during a follow-
up of more than 5 years. In contrast, in the 3 hospitals
(A, B, and C) using the ‘standard intensified’ pathology pro-
tocol, the 5-years regional recurrence risk was 2.6%.
Assuming that there is an absolute difference in the risk of
regional recurrence of 3% between the hospitals with a ‘stan-
dard intensified’ pathology protocol and those which performTable 3
Patient characteristics of patients with regional lymph node recurrence.
Patient Age-group Tumor size (cm) Histological
grade
Hormo
status
1  70 1.4 I ER and
2 50e59 1.5 II PgR þ
3  70 3.5 I ER þ
4 60e69 1.5 I ER þ
5 60e69 3.5 II ER þ
6 50e59 2.2 III ER and
7 70 0.8 I ER þ
8 70 1.5 II ER and
9 60e69 0.9 I ER þultra-staging of the SN, the question raises whether 37 extra
ALNDs per 100 patients are worthwhile in order to prevent
3 regional recurrences. It gives a ratio for number needed to
treat of approximately 1:13. In terms of morbidity of the sur-
gical procedure and in terms of costs, amore than ‘standard in-
tensified’ pathology protocol may thus not be of value.
Of note, during inclusion the national breast cancer guide-
lines of the Netherlands were quite conservative with respect
to the recommendations for adjuvant systemic therapy. Only 4
out of 9 patients who had a recurrence had received adjuvant
systemic therapy (Table 3). Nowadays, more patients with SN
micrometastases are treated with more effective systemic
therapy, such as anthracycline/taxane-containing regimens,
which are considered the most effective chemotherapy in
early breast cancer. If more patients would have had adjuvant
systemic therapy, the risk of relapse might have been lower.10
Further of note, 5 of 9 patients were treated with mastectomy
without radiotherapy. The excellent results of the Z0011 study
are thought to be related to the use of tangential radiotherapy
to the axilla as part of the for inclusion requested breast con-
serving surgery, and the use of systemic therapy in nearly all
patients.
In the years 2002 and 2003, it was within the Nether-
lands common practice that patients with isolated tumor
cells in the SN underwent a completion ALND,9 but during
later years this policy changed, in agreement with ASCO
guidelines. ASCO guidelines do not recommend a routine
ALND if just isolated tumor cells are detected in the SN.11
In literature, many single center series and 4 randomized
trials have been reported on axillary recurrence rates in pa-
tients with a negative SN.5,12e14 The reported recurrence
rates in these studies regarding SN negative patients seemne-receptor Systemic
therapy
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Figure 1. Cumulative risk for regional lymph node recurrence per hospital.
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pathology protocol was not or only briefly mentioned as
if this would not impact recurrence rate. In the first random-
ized trial on this topic, by Veronesi et al., it was reported
that a very intensive SN pathology protocol was used.15
In that particular study, approximately 15 pairs of sections
were cut at 50 mm intervals of each half of the SN, with ap-
proximately 60 sections per SN being examined. It is im-
portant to realize that the excellent follow-up results from
this center cannot simply be translated to other hospitals
if another pathology protocol is followed.
Also of note, in the aforementioned randomized Milan
study only patients with a tumor of 2 cm or less were in-
cluded, whereas currently in most centers the SN procedure
is implemented for patients having a tumor size of 5 cm or
less. This is of relevance, because, irrespective of SN find-
ings, the primary tumor characteristics are also strongly as-
sociated with risk of non-SN metastases.16
In fact, breast cancer-specific survival is the most rele-
vant endpoint to judge the clinical impact of the different
SN pathology protocols. To this end, still too few deaths
have occurred to draw conclusions with regard to differ-
ences in outcome between hospitals. We will continue to
collect follow-up information from this cohort on disease-
specific events, including breast cancer-related death.
In conclusion, we showed that hospital D performed
37% more completion ALNDs for no improvement in re-
gional recurrence rate as compared to hospitals A, B, and
C at 5 years follow-up. Whether the intensified SN pathol-
ogy protocol of hospital D proves to be of value in 10 years,
remains to be awaited. To this end, a SN pathology protocol
as is used in most centers nowadays, with on average 3
levels per paraffin block, seems to be adequate.Acknowledgments
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